| Basics |
T2 Biosystems, Inc.
T2 Biosystems Inc is an in vitro diagnostic company. It has developed the proprietary platform that enables direct detection of pathogens, biomarkers and other abnormalities across various unpurified patient sample types.
|
| IPO Date: |
August 7, 2014 |
| Sector: |
Healthcare |
| Industry: |
Medical Diagnostics and Research |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.17 | 4.83%
|
| Avg Daily Range (30 D): |
$0.02 | 75.00%
|
| Avg Daily Range (90 D): |
$0.02 | 41.31%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
5.82M |
| Avg Daily Volume (30 D): |
.01M |
| Avg Daily Volume (90 D): |
.03M |
| Trade Size |
| Avg Trade Size (Sh.): |
926 |
| Avg Trade Size (Sh.) (30 D): |
1,490 |
| Avg Trade Size (Sh.) (90 D): |
1,626 |
| Institutional Trades |
| Total Inst.Trades: |
103 |
| Avg Inst. Trade: |
$1.63M |
| Avg Inst. Trade (30 D): |
$.51M |
| Avg Inst. Trade (90 D): |
$.51M |
| Avg Inst. Trade Volume: |
.01M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$2.16M |
| Avg Closing Trade (30 D): |
$.51M |
| Avg Closing Trade (90 D): |
$.51M |
| Avg Closing Volume: |
21.44K |
|
|
| Financials |
| |
TTM |
Q3 2024 |
Q2 2024 |
|
Basic EPS
|
$-.03
|
$-.57
|
$-.64
|
|
Diluted EPS
|
$-.03
|
$-.57
|
$-.64
|
|
Revenue
|
$ 7.68M
|
$ 1.99M
|
$ 1.95M
|
|
Gross Profit
|
$
|
$
|
$
|
|
Net Income / Loss
|
$ -42.95M
|
$ -10.12M
|
$ -8.96M
|
|
Operating Income / Loss
|
$ -41.66M
|
$ -10.16M
|
$ -9.58M
|
|
Cost of Revenue
|
$
|
$
|
$
|
|
Net Cash Flow
|
$ -8.63M
|
$ M
|
$ M
|
|
PE Ratio
|
|
|
|
| Splits |
|
Oct 13, 2023:
1:100
|
|
Oct 13, 2022:
1:50
|
|
|
|
